Liquid blood tests to predict endometrial cancer return
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with endometrial cancer based on tissue testing
- You are scheduled for initial surgery, or you recently had your first surgery
- You can and will sign informed consent
- You have not had chemotherapy or radiation for endometrial cancer before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a blood test can find cancer returning earlier than usual scans, in people who had endometrial or cervical cancer. If you've finished or are on standard treatment, your blood may help show if the cancer comes back sooner.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This trial studies tumor DNA in blood and tissue from people with aggressive endometrial cancer to better understand the disease. You donate samples during surgery and follow-up visits.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study looks at blood samples from people with ovarian cancer to measure a marker called ctDNA (bits of tumor DNA in the blood). The goal is to see if changes in this marker before and after surgery can help predict or monitor the cancer.
This study tests two less invasive methods—sampling cells from the lining of the uterus (endometrial cytology) and checking DNA changes in the cervix—to see if they can help detect endometrial cancer or atypical hyperplasia, and to monitor response in people who are preserving their fertility. It aims to find a gentler alternative to traditional biopsy.
Hear when a new Endometrial Clear Cell Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.